Atika Capital Management’s Puma Biotechnology PBYI Stock Holding History

Atika Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-62,000	Closed	-$3.67M	–	99
2018 Q2	$3.67M	Buy	+62,000	New	+$3.59M	0.71%	54
2015 Q1	–	Sell	-2,500	Closed	-$473K	–	75
2014 Q4	$473K	Buy	+2,500	New	+$555K	0.35%	62
2014 Q2	–	Sell	-11,350	Closed	-$1.18M	–	74
2014 Q1	$1.18M	Buy	11,350 +8,450	+291%	+$993K	1.01%	42
2013 Q4	$300K	Buy	+2,900	New	+$170K	0.27%	58

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Atika Capital Management's PBYI Position: Q3 2018 in Review

Atika Capital Management sold out of Puma Biotechnology (PBYI) in Q3 2018, closing a stake of 62,000 shares — an estimated $3.67M sold.

Atika Capital Management first reported a position in PBYI in Q4 2013 and held it in 4 quarters. The position peaked at $3.67M in Q2 2018. 156 funds tracked by Wall St. Rank hold PBYI as of Q3 2018.

Atika Capital Management reported no remaining Puma Biotechnology position as of Q3 2018 after selling out during the quarter.
Atika Capital Management sold 62,000 Puma Biotechnology shares in Q3 2018, an estimated $3.67M.
Atika Capital Management first reported a position in Puma Biotechnology in Q4 2013 and held it in 4 quarters.
Atika Capital Management's Puma Biotechnology position peaked at $3.67M in Q2 2018.
156 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2018.

Based on Atika Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.